CA3059107A1 - Isoindolin-1-one derivatives and pharmaceutical compositions thereof useful as aski inhibitor - Google Patents
Isoindolin-1-one derivatives and pharmaceutical compositions thereof useful as aski inhibitor Download PDFInfo
- Publication number
- CA3059107A1 CA3059107A1 CA3059107A CA3059107A CA3059107A1 CA 3059107 A1 CA3059107 A1 CA 3059107A1 CA 3059107 A CA3059107 A CA 3059107A CA 3059107 A CA3059107 A CA 3059107A CA 3059107 A1 CA3059107 A1 CA 3059107A1
- Authority
- CA
- Canada
- Prior art keywords
- group
- compound
- 6alkyl
- c6alkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762482085P | 2017-04-05 | 2017-04-05 | |
| US62/482,085 | 2017-04-05 | ||
| PCT/US2018/026134 WO2018187506A1 (en) | 2017-04-05 | 2018-04-04 | Ask1 inhibitor compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3059107A1 true CA3059107A1 (en) | 2018-10-11 |
Family
ID=63712299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3059107A Pending CA3059107A1 (en) | 2017-04-05 | 2018-04-04 | Isoindolin-1-one derivatives and pharmaceutical compositions thereof useful as aski inhibitor |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US20210087167A1 (https=) |
| EP (1) | EP3606519B1 (https=) |
| JP (1) | JP7196093B2 (https=) |
| KR (1) | KR102665145B1 (https=) |
| CN (1) | CN110730661B (https=) |
| AR (1) | AR111407A1 (https=) |
| AU (1) | AU2018250217B2 (https=) |
| CA (1) | CA3059107A1 (https=) |
| CL (1) | CL2019002810A1 (https=) |
| CO (1) | CO2019011708A2 (https=) |
| CR (1) | CR20190503A (https=) |
| CU (1) | CU20190080A7 (https=) |
| DK (1) | DK3606519T3 (https=) |
| DO (1) | DOP2019000255A (https=) |
| EA (1) | EA201992299A1 (https=) |
| EC (1) | ECSP19078393A (https=) |
| ES (1) | ES2992084T3 (https=) |
| FI (1) | FI3606519T3 (https=) |
| HU (1) | HUE068103T2 (https=) |
| IL (1) | IL269711B (https=) |
| JO (1) | JOP20190221A1 (https=) |
| MA (1) | MA49047A (https=) |
| MX (1) | MX394098B (https=) |
| NI (1) | NI201900102A (https=) |
| NZ (1) | NZ758345A (https=) |
| PE (1) | PE20200009A1 (https=) |
| PH (1) | PH12019502288A1 (https=) |
| PL (1) | PL3606519T3 (https=) |
| PT (1) | PT3606519T (https=) |
| RU (1) | RU2019134679A (https=) |
| SG (1) | SG11201909155VA (https=) |
| SI (1) | SI3606519T1 (https=) |
| TW (1) | TWI779022B (https=) |
| WO (1) | WO2018187506A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| CN110869017B (zh) | 2017-05-12 | 2023-05-05 | 英安塔制药有限公司 | 细胞凋亡信号调节激酶1抑制剂及其使用方法 |
| CN111801314B (zh) | 2018-01-02 | 2023-10-31 | 西尔洛克治疗公司 | Ask1抑制剂化合物及其用途 |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| EP3787621B1 (en) | 2018-05-02 | 2024-12-18 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
| US10968199B2 (en) | 2018-08-22 | 2021-04-06 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2020106707A1 (en) | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| US11466033B2 (en) | 2019-03-25 | 2022-10-11 | Enanta Pharmaceuticals, Inc. | Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors |
| CN112409332B (zh) * | 2019-08-23 | 2023-12-08 | 广东东阳光药业股份有限公司 | 三氮唑衍生物及其在药物中的应用 |
| KR20220132543A (ko) | 2019-12-27 | 2022-09-30 | 루핀 리미티드 | 치환된 삼환 화합물 |
| CN115698004A (zh) | 2020-05-01 | 2023-02-03 | 辉瑞公司 | 作为hpk1抑制剂的氮杂内酰胺化合物 |
| WO2021224818A1 (en) * | 2020-05-08 | 2021-11-11 | Pfizer Inc. | Isoindolone compounds as hpk1 inhibitors |
| US20230271940A1 (en) * | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| JP2025525586A (ja) * | 2022-07-20 | 2025-08-05 | シール ロック セラピューティクス，インク． | 器官の疾患または障害をａｓｋ１阻害剤で処置する方法 |
| WO2025233319A1 (en) | 2024-05-06 | 2025-11-13 | Genfit | (1,2,4-triazol-3-yl)-2-pyridyl-1-isoindolinone for use in the treatment of sepsis |
| WO2026057806A1 (en) | 2024-09-13 | 2026-03-19 | Genfit | Injectable dosage form of 2-[6-(4-cyclopropyl-4h-1,2,4-triazol-3-yl)-2-pyridyl]-5-morpholinocarbonyl-1-isoindolinone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| PL2531501T3 (pl) * | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| WO2012079022A1 (en) * | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
| EP3197448B1 (en) * | 2014-09-24 | 2019-04-24 | Gilead Sciences, Inc. | Methods of treating liver disease |
| WO2017214359A1 (en) * | 2016-06-10 | 2017-12-14 | Venenum Biodesign Llc | Novel clostridium difficile toxin inhibitors |
| PL3572412T3 (pl) | 2017-01-22 | 2021-09-27 | Fujian Cosunter Pharmaceutical Co., Ltd. | Pochodna pirydyny jako inhibitor ask1 oraz sposób jej wytwarzania oraz zastosowanie |
| CN109071448B (zh) * | 2017-01-22 | 2020-03-17 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
| ES2926449T3 (es) | 2017-02-07 | 2022-10-26 | Biogen Ma Inc | Agentes inhibidores de ASK1 |
| WO2018149284A1 (zh) | 2017-02-16 | 2018-08-23 | 四川科伦博泰生物医药股份有限公司 | 激酶抑制剂及其制备方法和用途 |
| WO2018151830A1 (en) | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| CN115504986B (zh) | 2017-03-03 | 2024-05-14 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| WO2018183122A1 (en) | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
| EP3681499A4 (en) | 2017-09-13 | 2021-04-21 | D.E. Shaw Research, LLC | CONNECTIONS AS RAS INHIBITORS AND THEIR USE |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
-
2017
- 2017-06-16 JO JOP/2019/0221A patent/JOP20190221A1/ar unknown
-
2018
- 2018-04-03 TW TW107111742A patent/TWI779022B/zh active
- 2018-04-04 NZ NZ758345A patent/NZ758345A/en unknown
- 2018-04-04 PL PL18780760.7T patent/PL3606519T3/pl unknown
- 2018-04-04 FI FIEP18780760.7T patent/FI3606519T3/fi active
- 2018-04-04 EA EA201992299A patent/EA201992299A1/ru unknown
- 2018-04-04 PT PT187807607T patent/PT3606519T/pt unknown
- 2018-04-04 RU RU2019134679A patent/RU2019134679A/ru not_active Application Discontinuation
- 2018-04-04 HU HUE18780760A patent/HUE068103T2/hu unknown
- 2018-04-04 PE PE2019001990A patent/PE20200009A1/es unknown
- 2018-04-04 WO PCT/US2018/026134 patent/WO2018187506A1/en not_active Ceased
- 2018-04-04 SG SG11201909155V patent/SG11201909155VA/en unknown
- 2018-04-04 SI SI201831140T patent/SI3606519T1/sl unknown
- 2018-04-04 JP JP2019553366A patent/JP7196093B2/ja active Active
- 2018-04-04 CA CA3059107A patent/CA3059107A1/en active Pending
- 2018-04-04 CU CU2019000080A patent/CU20190080A7/es unknown
- 2018-04-04 DK DK18780760.7T patent/DK3606519T3/da active
- 2018-04-04 MA MA049047A patent/MA49047A/fr unknown
- 2018-04-04 US US16/499,075 patent/US20210087167A1/en not_active Abandoned
- 2018-04-04 CN CN201880037304.1A patent/CN110730661B/zh active Active
- 2018-04-04 EP EP18780760.7A patent/EP3606519B1/en active Active
- 2018-04-04 MX MX2019012013A patent/MX394098B/es unknown
- 2018-04-04 ES ES18780760T patent/ES2992084T3/es active Active
- 2018-04-04 CR CR20190503A patent/CR20190503A/es unknown
- 2018-04-04 AU AU2018250217A patent/AU2018250217B2/en active Active
- 2018-04-04 KR KR1020197032180A patent/KR102665145B1/ko active Active
- 2018-04-05 AR ARP180100846A patent/AR111407A1/es active IP Right Grant
- 2018-05-03 US US15/970,587 patent/US10150755B2/en active Active
-
2019
- 2019-09-26 IL IL269711A patent/IL269711B/en unknown
- 2019-10-02 CL CL2019002810A patent/CL2019002810A1/es unknown
- 2019-10-03 NI NI201900102A patent/NI201900102A/es unknown
- 2019-10-03 PH PH12019502288A patent/PH12019502288A1/en unknown
- 2019-10-04 DO DO2019000255A patent/DOP2019000255A/es unknown
- 2019-10-23 CO CONC2019/0011708A patent/CO2019011708A2/es unknown
- 2019-10-31 EC ECSENADI201978393A patent/ECSP19078393A/es unknown
-
2024
- 2024-09-26 US US18/897,798 patent/US20250304552A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018250217B2 (en) | ASK1 inhibitor compounds and uses thereof | |
| RU2610840C2 (ru) | Тиазолопиримидины | |
| JP7692353B2 (ja) | マトリプターゼ２阻害剤及びその使用 | |
| CA2881688A1 (en) | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof | |
| CA2890671A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| CN109810041A (zh) | 卤代烯丙基胺类ssao/vap-1抑制剂及其应用 | |
| CA3066946A1 (en) | Heteroaromatic compounds as vanin inhibitors | |
| KR20170044204A (ko) | 오렉신―１ 수용체의 억제제로서의 치료 화합물 | |
| CA3041033A1 (en) | Monocyclic compounds useful as gpr120 modulators | |
| US12427146B2 (en) | C-terminal SRC kinase inhibitors | |
| EP2931721A1 (en) | Thiazole derivatives as inhibitors of bruton's tyrosine kinase | |
| KR101368079B1 (ko) | Ｊｎｋ 의 억제제 | |
| CA2567352A1 (en) | 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes | |
| EP4125895A1 (en) | Potent and selective irreversible inhibitors of irak1 | |
| CN103443107A (zh) | 噻唑并嘧啶化合物 | |
| EA040632B1 (ru) | Соединения, ингибирующие ask1, и их применение | |
| BR112019021021B1 (pt) | Compostos de inibidor de ask1, usos dos mesmos e composições farmacêuticas | |
| HK40013582B (en) | Ask1 inhibitor compounds and uses thereof | |
| HK40013582A (en) | Ask1 inhibitor compounds and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230323 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20240823 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241128 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250328 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250328 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250419 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250419 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250616 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250620 |